Search
Vivos Therapeutics Inc
VVOSAdd to Watchlist
0.091USD
+0.005+5.81%
Close 11-11 16:00（ET）
3.06MMarket Cap
LossP/E TTM
Pre-market 06:28 (ET)0.094USD+0.003+3.30%
Pre-market 06:28 (ET)Vivos Therapeutics Inc (VVOS) Stock Price Target & Forecast
Analyst Rating
Based on 3 analysts giving stock ratings to Vivos Therapeutics Inc in the past month.
Buy
0 Strong Buy
2 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
2.117USD+1759.99%
VVOS Analyst Recommendation Trends
In the current month, VVOS has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VVOS average Analyst price target in the last month is 2.117.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
VVOS Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Stryker Corp
SYK
10
14
6
0
0
30
Dexcom Inc
DXCM
13
12
4
0
0
29
Medtronic PLC
MDT
8
11
10
0
0
29
Abbott Laboratories
ABT
11
13
4
0
0
28
Guardant Health Inc
GH
12
14
2
0
0
28
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Zimmer Biomet Holdings Inc
ZBH
2
5
20
0
0
27
Insulet Corp
PODD
7
7
12
0
0
26
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Repligen Corp
RGEN
5
12
4
0
0
21
Financial Forecasting
Based on analysts' estimates, VVOS EPS is projected to reach -0.320 in FY2026Q3, following reported EPS of -0.310 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.48
-0.45
-0.39
-0.32
-0.26
Actual
-0.55
-0.52
-0.31
--
--
Surprise
-14.81%
-15.80%
+19.83%
--
--
FAQs
What is Vivos Therapeutics Inc's expected revenue for the next quarter?
Vivos Therapeutics Inc's expected revenue is 5.94M.
What is Vivos Therapeutics Inc's price target?
Analysts forecast that Vivos Therapeutics Inc's price target is USD 2.12, with the highest forecast at USD 3.10 and the lowest forecast at USD 0.75.
How have Vivos Therapeutics IncVVOS's recent earnings per share performed?
The market expectation was USD -0.31, while Vivos Therapeutics IncVVOS's earnings per share (EPS) for the previous quarter was USD -0.52. EPS for the next quarter is expected at USD -0.32.
What is the analyst rating for Vivos Therapeutics Inc?
Based on the ratings of Vivos Therapeutics Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.